Isotonic Versus Hypotonic Fluid for Maintenance IV Therapy
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Hyponatremia associated with administration of hypotonic intravenous (IV) fluids may have serious complications. It has recently been suggested that isotonic saline may be a more appropriate choice of maintenance IV fluid. This pilot and feasibility study aims to compare isotonic saline to 0.45% saline in hospitalized children requiring parenteral fluid support in order to:
Aim 1: To determine the feasibility of conducting a double-blind, randomized controlled trial comparing these solutions.
Aim 2a: To compare the rate of change in serum Na (mmol/L/hr) and the incidence of hyponatremia (Na <136 mmol/L) between patients receiving isotonic and hypotonic intravenous fluids at at least 50% of the traditional maintenance rate for an interval of at least 8 hours.
Aim 2b: To compare the incidence of adverse events between the two IV fluid treatment groups.
| Condition | Intervention | Phase |
|---|---|---|
|
Gastroenteritis Bronchiolitis Sepsis Urinary Tract Infection |
Drug: 0.9% saline in 5% dextrose (intravenous) Drug: 0.45% saline in 5% dextrose (intravenous) |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Isotonic Versus Hypotonic Saline for Maintenance Intravenous Fluid Therapy: A Pilot Randomized Trial |
- rate of change in serum sodium [ Time Frame: 8 to 20 hours ] [ Designated as safety issue: Yes ]
- hypertension [ Time Frame: 8 to 20 hours ] [ Designated as safety issue: Yes ]
- congestive heart failure [ Time Frame: 8 to 20 hours ] [ Designated as safety issue: Yes ]
| Enrollment: | 38 |
| Study Start Date: | January 2007 |
| Study Completion Date: | April 2008 |
| Primary Completion Date: | April 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: A
0.9% saline in 5% dextrose (intravenous)
|
Drug: 0.9% saline in 5% dextrose (intravenous)
Other Name: isotonic saline
|
|
Active Comparator: B
0.45% saline in 5% dextrose (intravenous)
|
Drug: 0.45% saline in 5% dextrose (intravenous) |
Eligibility| Ages Eligible for Study: | 1 Month to 18 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 1 month to 18 years of age
- Require IV fluids for at least 8 hr.
- Baseline serum sodium >=136 mmol/L & <=145 mmol/L
Exclusion Criteria:
- Baseline serum sodium concentration less than 136 mmol/L or greater than 145 mmol/L
- Renal disease, a history of cardiac dysfunction or evidence of cardiac dysfunction, pre-existing hypertension, diuretic use, edema, or known adrenal dysfunction
- Acute neurological illness such as meningitis or encephalitis
- Severe chronic neurological illnesses (uncontrolled seizure disorders, severe developmental delay)
Contacts and Locations| Canada, Quebec | |
| Montreal Children's Hospital | |
| Montreal, Quebec, Canada, H3H 1P3 | |
| Principal Investigator: | Bethany J Foster, MD, MSCE | Montreal Children's Hospital Research Institute |
More Information
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Dr. Bethany Foster, Montreal Children's Hospital |
| ClinicalTrials.gov Identifier: | NCT00457873 History of Changes |
| Other Study ID Numbers: | PED-06-016 |
| Study First Received: | April 5, 2007 |
| Last Updated: | May 20, 2008 |
| Health Authority: | Canada: Ethics Review Committee |
Keywords provided by McGill University Health Center:
|
surgery |
Additional relevant MeSH terms:
|
Bronchiolitis Gastroenteritis Sepsis Urinary Tract Infections Bronchitis Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases |
Respiratory Tract Infections Gastrointestinal Diseases Digestive System Diseases Infection Systemic Inflammatory Response Syndrome Inflammation Pathologic Processes Urologic Diseases |
ClinicalTrials.gov processed this record on May 16, 2013